Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time

Pharmacotherapy

Volumn 19, Issue 6, 1999, Pages 760-766

  Rosborough, Terry K ^a  

^a ABBOTT NORTHWESTERN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; THROMBOPLASTIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG DOSE; DRUG MONITORING; HEPARINIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTICOAGULANTS; COHORT STUDIES; DRUG MONITORING; FACTOR XA; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES;

EID: 0033059794     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.9.760.31547     Document Type: Article

References (34)

1. Estes JW. The heterogeneity of the anticoagulant response to heparin. J Clin Pathol 1972;25:45-8.
2. Hirsh J, van Aken WG, Callus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976;53:691-5.
3. Simon TL, Hyers TM, Gaston JP, Marker LA. Heparin pharmacokinetics: increased requirements in pulmonary embolism. Br J Haematol 1978;39:111-20.
4. Talstad I. Heparin therapy adjusted for body weight. Am J Clin Pathol 1985;83:378-81.
5. Juhan-Vague I, Riera H, Ailaud MF, Verdet D, Sambuc R. Measurement of blood heparin levels - variation in results with assay method. Thromb Haemost 1982;47:295.
6. Marci CD, Prager D. A review of the clinical indications for the plasma heparin assay. Am J Clin Pathol 1993;99:546-50.
7. Hirsh J, Warketin TE, Raschke R, Granger C, Ohman EM, Dalen J. Heparin and low-molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114: 489s-510.
8. Olson JD, Arkin CF, Brandt JT, et al. College of American pathologists conference XXXI on laboratory monitoring of anticoagulant therapy - laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998;122:782-98.
9. Beermann B, Lahnborg G. Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine. Thromb Haemost 1981;45:24-6.
10. Ellison MJ, Sawyer WT, Mills TC. Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 1989;8:65-8.
11. Holm HA, Kalvenes S, Abildgaard U. Changes in plasma antithrombin during intravenous heparin therapy: observations in 198 patients with deep venous thrombosis Scand J Haemost 1985;35:564-9.
12. Groce JB, Gal P, Douglas JB, Steuterman MC. Heparin dosage adjustment in patients with deep vein thrombosis using heparin concentrations rather than activated partial thromboplastin time. Clin Pharm 1987;6:216-22.
13. Rosborough TK. Comparison of antifactor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients. Am J Clin Pathol 1997;108:662-8.
14. Robinson JD, Lupkiewicz SM, Palenik L, Lopez LM, Ariel M. Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm 1983; 40:1016-19.
15. Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962;51:224-32.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
17. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurement in medical research. BMJ 1990;300: 230-5.
18. Edson JR, Krivit W, White J. Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med 1967;70:463-70.
19. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56.
20. Soloway HG, Cornell BM, Grayson JW. Comparison of various aclivated partial thromboplastin reagents in the laboratory control of heparin therapy. Am J Clin Pathol 1973;59:587-90.
21. Whitfield LR, Schentag JJ, Levy G. Relationship belween concentration and anticoagulant effect of heparin in plasma of hospitalized patients: magnitude and predictability of interindividual differences. Clin Pharmacol Ther 1982;32: 503-16.
22. Kearon C, Johnston M, Moffat K, McGinnis J, Ginsberg JS. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med 1998;158:1140-3.
23. Lenahan JG, Phillips GE. Some variables which influence the activated partial thromboplastin time assay. Clin Chem 1966;12:269-73.
24. Harmeling JG, Cordray DR. The activated partial thromboplastin time as a control in heparin therapy. South Med J 1967;60:594-8.
25. Hirsh J, Gallus AS. The activated partial thromboplastin time [letter]. N Engl J Med 1973;288:1410.
26. Sibley C, Singer JW, Wood RJ. Comparison of activated partial thromboplastin reagents. Am J Clin Pathol 1973;59:581-6.
27. Poller L, Thomson JM, Palmer MK. Measuring partial thromboplastin time - an international collaborative survey. Lancet 1976;2:842-6.
28. Triplett DA, Harms CS, Koepke JA. The effecl of heparin on the activated partial thromboplastin time. Am J Clin Pathol 1978;70(3 suppl):556-9.
29. Shojania AM, Tetreault J, Turnbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol 1988;89:19-23.
30. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-9.
31. Rachakonda V, Rachakonda L, Belliveau RR. aPTT in heparinized patients: influence of the interval between sampling and lesting. Clin Appl Thromb Hemost 1998;4:213-16.
32. Godal HC. A comparison of two heparin-neutralizing agents: protamine and polybrene. Scand J Clin Lab Invest 1960;12:446.
33. Gauvin GP, Umlas J, Chin N. Measurement of plasma heparin levels using a fluorometric assay: an evaluation of the Protopalh system. Med Instrum 1983;17:165-8.
34. Pierson-Perry JF, Obzansky DM, Mizzer JP. Development and characterization of an automated assay of effective heparin activity in plasma. Clin Chem 1987;33:1630-4.